Genomic loss of heterozygosity and survival in the REAL3 trial.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers will have high-LOH which would be prognostic in patients treated with platinum chemotherapy.

Methods

Diagnostic biopsy DNA from patients treated in the REAL3 trial was sequenced using the Foundation Medicine T5 next-generation sequencing (NGS) assay. An algorithm quantified the percentage of interrogable genome with LOH. Multidimensional optimization was performed to identify a cut-off dichotomizing the population into LOH-high and low groups associated with differential survival outcomes.

Results

Of 158 available samples, 117 were successfully sequ

SUBMITTER: Smyth EC 

PROVIDER: S-EPMC6291175 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature